Rainwater Charitable Foundation announces partnership with drug discovery teams at Oxford University
The partnership aims to accelerate the translation of discoveries in disease biology into new treatments for patients with tauopathies.
FORT WORTHTexas , June 2, 2022 /PRNewswire/ — The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered into a partnership with Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to University of Oxford. This partnership aims to accelerate the development of new therapies for the treatment of tauopathies, a group of progressive neurodegenerative diseases.
The RCF and ARUK-ODDI will work together to take discoveries made by principal investigators within the Tau consortium through the “valley of death” of drug discovery by applying an integrated drug discovery approach to advance these discoveries up to the clinic. ARUK-ODDI brings best practice in target validation, assay development and execution, computational chemistry and medicinal chemistry supported by ADME. The in-depth knowledge of the basic discovery biology and mechanisms of tauopathy derived from the principal investigators of the Tau Consortium will complement the drug discovery expertise of the ARUK-ODDI team. This partnership aims to pave the way for future partnerships to enable clinical development and commercialization.
“This collaborative partnership is a significant step forward in our plans to bring potential treatments closer to the clinic for patients with tauopathies,” said Leticia Toledo-Sherman, PhD., Senior Director of Drug Discovery for the Tau Consortium. at RCF. “The Oxford DDI team combines a deep understanding of Alzheimer’s disease, primary tauopathies and neuroinflammation with critical expertise in drug discovery. This combination and their experience in bringing academic programs to the clinic will be critical to the success of our therapeutic development efforts.
Teacher John DavisBusiness Development Director of the Alzheimer’s Research UK Drug Discovery Alliance, said:
“The Rainwater Charitable Foundation’s Tau Consortium has given many of the world’s top tau research teams a unifying alliance that results in faster progress toward identifying the key molecular mechanisms at play in tauopathies and diseases. painful neurodegenerative diseases they cause. The Alzheimer’s Research UK Oxford Drug Discovery Institute at University of Oxford is delighted to partner with the RCF to advance the translation of the latest scientific advances into new therapeutic approaches, which we hope will ultimately benefit patients.”
About the Rainwater Charitable Foundation and the Tau Consortium
The Rainwater Charitable Foundation (RCF) was established in the early 1990s by a renowned private investor and philanthropist. Richard E. Rainwater. The RCF supports a range of programs in K-12 education, medical research, and other worthy causes. To fulfill its mission of accelerating the development of new diagnostics and treatments for tau-related neurodegenerative disorders, the RCF medical research team operates the Tau Consortium and Rainwater Prize programs. With over $145 million invested to date, the RCF has helped advance eight treatments into human trials. For more information, please visit http://rainwatercharitablefoundation.org/, www.rainwaterprize.organd https://tauconsortium.org/.
About Alzheimer’s Research UK Oxford Drug Discovery Institute
The Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Center for Medicines Discovery (CMD) of University of Oxford. The CMD is a collection of research teams within the Nuffield Department of Medicine with complementary disciplines and a unifying mission to conduct translational biology and discover new therapeutic approaches. ARUK-ODDI was founded in 2014 with a £10 million grant from Alzheimer’s Research UK, which was renewed in 2020, and is part of a Drug Discovery Alliance, funded by the charity , with parallel institutes in Cambridge and London (UK). ARUK-ODDI comprises scientific experts in cellular and molecular neurobiology, molecular pharmacologists, screening experts, computational and medical chemists co-located in world-class facilities at the heart of the University of Oxford biomedical campus. ARUK-ODDI’s mission is to develop new targets, identified by academic collaborators, and, through collaboration, to provide chemical lead series and proof-of-concept studies that justify further development.
About Alzheimer’s Research UK
Alzheimer’s Research UK is the UK’s leading charity specializing in finding preventions, treatments and a cure for dementia. Our animation “What is dementia?” explains the basics of dementia and the diseases that cause it What is dementia? Alzheimer’s Research UK – YouTube
Alzheimer’s Research UK is currently supporting pioneering dementia research projects worth nearly £34 million (equivalent to 47 million US dollars) at leading universities in the UK. Learn more about www.alzheimersresearchuk.org and help us better understand dementia.
Glenn A. Harris
Director of Business Development and Research Partnerships
Charitable Rainwater Foundation
SOURCE The Rainwater Charitable Foundation